New medicines are continuously being developed for existing and new diseases. The early phases of drug development include clinical studies performed by pharmaceutical companies to determine safety and efficacy in healthy volunteers. At this stage the drug is still under development and therefore generally is not in its final dose form yet. During this phase, using an oral liquid makes it easier to adjust dosing for different patient groups.
SyrSpend® SF is a GMP produced, oral liquid suspension base with a broad compatibility for APIs from different pharmaceutical classes. Fagron is happy to announce that SyrSpend® SF is currently being recognized by large pharmaceutical companies for its quality and compatibility, as is demonstrated by the fact that two big pharmaceutical companies are using the product for their clinical trials in both children and adults.
The SyrSpend® SF vehicle range is supported by science, complies with the highest quality standards and is globally available. If you would like to learn more about SyrSpend® SF, please contact us.